Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZBio1 in Healthy Chinese Volunteers
NCT04765995Phase 1Completed
- Sponsor
- Hangzhou Grand Biologic Pharmaceutical Inc.
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HZBio1 in hyperuricemia (5 arms), sponsored by Hangzhou Grand Biologic Pharmaceutical Inc. Primary endpoints: Percentage of Participants With Adverse Events at 36 days, Tmax of HZBio1 at 36 days and 8 more. Started Mar 2021; status: completed.
02
Drugs
HZBio1
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT04765995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765995.